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Abstract
Melanoma is one of the most lethal cancers when it reaches a metastatic stage. Despite advancements in targeted
therapies (BRAF inhibitors) or immunotherapies (anti-CTLA-4 or anti-PD1), most patients with melanoma will need
additional treatment. Thus, there is an urgent need to develop new therapeutical approaches to bypass resistance and
achieve more prolonged responses. In this context, we were interested in E2F1, a transcription factor that plays a major
role in the control of cell cycle under physiological and pathological conditions. Here we conﬁrmed that E2F1 is highly
expressed in melanoma cells. Inhibition of E2F1 activity further increased melanoma cell death and senescence, both
in vitro and in vivo. Moreover, blocking E2F1 also induced death of melanoma cells resistant to BRAF inhibitors. In
conclusion, our studies suggest that targeting the E2F1 signaling pathway may be therapeutically relevant for
melanoma.
Introduction
Cutaneous melanoma is one of the most lethal cancers
among young adults. Melanoma has a high capability of
rapid invasion and metastasizes to other organs. When
lymph nodes metastase, the prognosis worsens con-
siderably with a survival rate of 50% at 5 years. The
increased knowledge about the molecular mechanisms
of melanoma has revolutionized its treatment.
Approximately half of melanomas express mutations in
the protein kinase BRAF (such as BRAFV600E) that
constitutively activate the mitogen-activated protein
kinase (MAPK) pathway and result in a dysregulated
proliferation irrespective of the presence of growth fac-
tors. The BRAF mutation constitutes a potential target for
new anti-melanoma treatments, and the BRAF inhibitors
vemurafenib and dabrafenib have demonstrated an
improvement in both overall survival and progression-free
survival1. Unfortunately, despite encouraging response
rates seen using BRAF inhibitors, relapses usually occur
within months after treatment2. Over the past 2 years,
tremendous efforts have been directed toward under-
standing the molecular mechanisms of acquired BRAF
inhibitor resistances3,4. Further, immunotherapies such as
anti-CTLA-4 or anti-PD1 antibodies, which reactivate the
immunity response of the patient, achieve durable
responses or stable disease, but only in approximately 10
to 35% of patients5. Thus, there is an urgent need to
develop new therapeutic approaches to bypass resistance
and achieve more prolonged responses.
Cell proliferation is a tightly regulated process that
comprises cyclins, cyclin-dependent kinases (CDKs),
transcription factors, and CDK inhibitors6. The E2F1
transcription factor plays a major role in the control of
cell cycle, in physiological and pathological conditions7.
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Deciphering the bona ﬁde target genes of E2F1 demon-
strated the key roles for this transcription factor in the
regulation of cellular and tissue functions. Indeed, apop-
tosis, senescence, and glucose homeostasis are important
mechanisms ﬁnely tuned by E2F1. Interestingly, recent
data demonstrated that the overexpression of this factor is
found in several types of cancers8. Altogether, these data
suggest E2F1 as a potential therapeutic target for cancer
cells. While E2F proteins, in particular E2F1, have
emerged as critical players in melanoma development9–11,
our mechanistic understanding of its regulation and
function remains limited. Here, we report a key role for
E2F1 in the control of melanoma cell death and drug
sensitivity. E2F1 is highly expressed in melanoma cells.
Depletion of E2F1 using small interfering RNA (siRNA)
or pharmacological blockade of E2F activity further
increased melanoma cell death and senescence, both
in vitro and in vivo. Death and senescence induced by
inhibition of E2F1 are as a result of p53 and p27 activa-
tion. Moreover, blocking E2F1 also induced death of
melanoma cells resistant to BRAF inhibitors, and E2F1
inhibition increases sensitivity of melanoma cells to BRAF
inhibitors. Our studies suggest that targeting the
E2F1 signaling pathway may be therapeutically relevant
for treatment of melanoma patients.
Results
E2F1 is overexpressed in melanoma
Using publically available microarray data12, we ana-
lyzed E2F1 expression and detected increased E2F1
mRNA levels in human melanoma biopsies compared to
healthy skin and naevus (Fig. 1a). Interestingly, in a cohort
of patients, followed in a clinic for 3 years after excision of
metastatic lesions13, those with high E2F1 showed sig-
niﬁcantly lower survival (Fig. 1b). Using immunohistolo-
gical analysis of human biopsies, we detected
E2F1 staining in primary melanoma, with a robust
expression in metastatic melanoma. E2F1 protein levels
were not detected in non-cancerous tissues including skin
and naevi (Fig. 1c and Table 1). By probing a panel of
primary and metastatic melanoma cell lines and human
melanocytes, we found that E2F1 is also strongly expres-
sed in different melanoma cell lines and in melanoma cells
freshly isolated from patients (Fig. 1d). Altogether, these
ﬁndings conﬁrm that E2F1 is highly expressed in mela-
noma cells.
Inhibition of E2F1 has an anti-proliferative effect on
melanoma cells
To assess whether E2F1 modulates the proliferation of
melanoma cells, we developed two complementary
approaches to inhibit E2F1 expression and/or activity.
First, depletion of E2F1 by two different siRNA resulted in
the inhibition of cellular viability in a time-dependent
manner (Fig. 2a). These results were replicated using
several melanoma cells with different mutational status
(Fig. 2b). We observed that the genetic inhibition of E2F1
induced loss of viability of these cancer cells. Interestingly,
TP53-mutated cell lines (Sk-Mel 28 and the patient cells
C-13.08) were resistant to E2F1 inhibition (Fig. 2b). In the
complementary fashion, the use of pharmacological
inhibitors of E2F1 and E2F4, HLM0064749, demonstrated
the same effect on inhibition of cell viability (Supp Fig-
ure 1A and B). In parallel, we have evaluated some rele-
vant E2F1 target genes by real-time quantitative reverse
transcription PCR (qRT-PCR) after inhibition of E2F1
using siRNA or pharmacological inhibitor (Supp Fig-
ure 1C). Some genes such as BIRC5, CDC6, or BRCA1 are
inhibited in the same way by siE2F1 and HLM006474 and
other genes such BCL2 or C-jun are inhibited only by
siE2F1.
We observed that inhibition of E2F1 does not affect
E2F4 expression (Supp Figure 1D), suggesting a speciﬁcity
of siRNA for E2F1. Interestingly, in the cohort of Bogu-
novic’s patients13, patients with high E2F4 did not have
lower survival rates (Supp Figure 1E). We next observed
that normal melanocytes and keratinocytes were resistant
to the HLM006474 inhibitor (Supp Figure 1F). Finally, we
tested HLM006474 in mice using xenograft experiments.
Six days after injection of A375 in immunodeﬁcient mice,
we treated them with the vehicle or HLM006474 (2 mg
per day per mouse) by intraperitoneal injection for 8 days
and we followed their tumor development. Mice treated
with HLM006474 demonstrated signiﬁcantly reduced
tumor growth compared to vehicle-treated animals (Supp
Figure 1G). A strong decrease in the tumor weight and
size were observed in mice treated with HLM006474
(Supp Figure 1H).
Since the genetic inhibition of E2F1 in melanoma cells
that are mutated for p53 does not affect their viability, we
hypothesized an implication of the p53 pathway. To test
this, we performed different sets of experiments. First, we
used a construct of p53-responsive elements fused to the
luciferase reporter and observed that inhibition of E2F1 by
siRNA led to transcriptional activation of p53 (Fig. 2c).
This was conﬁrmed by Western blot in two separate
melanoma cell lines (A375 and 1205Lu) as well as in
primary human melanoma cells (Fig. 2d). Interestingly,
HLM006474 induced the same effect on p53 expression
level (Supp Figure 2A), and tumors of HLM006474-
treated mice had increased levels of p53 (Supp Figure 2B).
Immunoﬂuorescence experiments revealed that inhibition
of E2F1 led to an increase expression and a nuclear
localization of p53 (Fig. 2e and Supp Figure 2C).
To further decipher the functional contribution of p53
in E2F1-mediated control of melanoma cell proliferation,
we silenced p53 expression in A375 cells and human
melanoma cells freshly isolated from patient. Blocking
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p53 expression abrogated the decreased viability induced
by E2F1 inhibition (Fig. 2f). Conversely, we performed
rescue experiments in p53-mutated Mewo and SK-Mel 28
cells using an adenoviral approach. Although no effects on
cell viability was observed when cells were transduced
with the control adenovirus, wild-type p53 overexpression
sensitized Mewo and SK-Mel 28 cells to E2F1 inhibition
and reduced their cellular viability (Fig. 2g).
Collectively, these results suggest that the effects of
E2F1 inhibition on melanoma cell death requires p53
activation and demonstrates that the E2F1 pharmacolo-
gical inhibition may control tumor development in mice.
E2F1 inhibition induces cell cycle arrest and apoptosis
To further understand the molecular mechanisms
linking E2F1 and melanoma cell viability, we measured
cell cycle phases by propidium iodide (PI) labeling in
A375 melanoma cells. Inhibiting E2F1 by siRNA induced
an arrest in the G1 phase and HLM006474 induced an
arrest in the G2/M phase (Supp Figure 3a). We conﬁrmed
these results by immunoblot (data not shown). We also
determined apoptosis by performing a double Annexin V
+DAPI (4',6-diamidino-2-phenylindole) labeling in A375
melanoma cells. Inhibiting E2F1 by siRNA or

















































Fig. 1 E2F1 is overexpressed in melanoma. a Level of E2F1 expression by microarray in healthy skin (n= 7), nevi (n= 18), and melanoma (n= 45)
(GEOD318912) (boxplots, Mann–Whitney test). b Survival of melanoma patients with high and low (above or below the median, respectively) E2F1
mRNA. Gene expression data of 44 metastatic melanoma tissues13 were used to deﬁne high and low expressor groups (boxplots, Mann–Whitney test)
and to generate Kaplan–Meier curves (log-rank test). c Representative immunostaining of E2F1 in normal skin and in different melanoma samples. d
E2F1 expression in different melanoma cells and in normal human melanocytes (NHM) analyzed by western blot. HSP90 was used as A loading
control. Signals were quantiﬁed using the Image J Software
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V+DAPI-positive cells, characteristic of apoptosis
(Fig. 3a and Supp Figure 3B). This effect was associated
with decreased levels of the anti-apoptotic protein Bcl-2,
increased poly (ADP-ribose) polymerase (PARP) cleavage,
and decreased zymogen form of caspase-3 (Fig. 3a and
Supp Figure 3B). These results were conﬁrmed in other
melanoma cells (Fig. 3b, c and Supp Figure 3C and D) and
tumors of mice injected with the E2F inhibitor (Supp
Figure 3E). As expected, caspase-3 activation was
observed after E2F1 inhibition (Fig. 3d). Flow cytometry
measurements of apoptosis after silencing caspase-3 fur-
ther demonstrated its contribution to apoptosis following
E2F1 inhibition (Fig. 3e). Blocking caspase-3 or p53 by
siRNA inhibited the cleavage of PARP (Fig. 3e), con-
ﬁrming that both caspase-3 and p53 are necessary to
induce apoptosis upon E2F1 inhibition.
E2F1 inhibition leads to a p53-dependent program of
senescence
Although we demonstrated that apoptosis contributed
to the observed effect on cell proliferation, this process
only partially restored the loss of cellular proliferation
induced by the inhibition of E2F1 (Fig. 4a). This indicated
that other mechanisms could contribute to reduced cell
viability. Flow cytometry experiments demonstrated that
the inhibition of E2F1 led to an increase in size and the
granularity of melanoma cells (Fig. 4b and Supp Figure 4A
and B), which are morphological characteristics of cellular
senescence14. Inhibition of E2F1 increased the β-
galactosidase activity of melanoma cells (Fig. 4c and
Supp Figure 4C). The senescence program is associated
with induction of DNA damage and increased 53BP1 foci
in damaged cells. After inhibition of E2F1, immuno-
ﬂuorescence analysis conﬁrmed increased 53BP1 foci in
cells with altered E2F1 activity (Fig. 4d and Supp Fig-
ure 4D). The induction of DNA damage following the
inhibition of E2F1 correlated with increased amount of
phospho (p)-CHK2 and γH2AX protein, two markers of
this process (Fig. 4e and Supp Figure 4E). We also
observed p38 activation and a concomitant decrease in c-
Myc and phosphorylated (p)-Rb, as well as an increase in
p27 and p21 activation (Fig. 4e and Supp Figure 4E).
These results were conﬁrmed in other melanoma cells
and in tumors of mice treated with E2F inhibitor (Supp
Figure 4F and G).
We next determined whether p53 and p27 were key
mediators of the senescence program triggered by E2F1
inhibition, and whether apoptosis and senescence were
two independent mechanisms that contributed to reduce
cell viability. siRNA-mediated inhibition of caspase-3
demonstrated increased size and granularity (Fig. 4f)
and β-galactosidase staining (Fig. 4g) of melanoma cells.
Moreover, these effects were associated with increased
p21, p27, p-Chk2, and γH2AX protein but decreased p-Rb
(Fig. 4h). In contrast, siRNA-mediated inhibition of p53 or
p27 did not increase the size or the granularity of the cells
(Fig. 4f), nor β-galactosidase activity (Fig. 4g) or p21, p27,
p-Chk2, γH2AX, and p-Rb (Fig. 4h).
Our results indicate that the process of senescence
induced by the inhibition of E2F1 is dependent on the p53
and p27 and that apoptosis and senescence may occur
independently. Finally, we determined that siE2F4 are also
able to induce death of melanoma cells by apoptosis.
However, contrary to siE2F1, siE2F4 did not induce
senescence (Supp Figure 5).
E2F1 inhibition increases sensitivity of the melanoma cells
to BRAF inhibitors and induces the death of the
vemurafenib-resistant melanoma cells
We next wondered whether inhibiting E2F1 could
potentiate the effects of the BRAF inhibitors, vemurafenib
(PLX4032) and dabrafenib. We ﬁrst assessed the effect of
PLX4032 on E2F1 and E2F4 levels and we observed that
BRAF inhibitors, PLX4032 and dabrafenib, reduce E2F1
and E2F4 levels (Fig. 5a). Second, we investigated whether
E2F1 depletion acts synergistically with BRAF inhibitors
to enhance its pro-apoptotic effect on melanoma cells.
Whereas increasing doses of PLX4032 or dabrafenib or
Table 1 The intensity and cytoplasm localization of the E2F1 staining in normal skin and in different melanoma samples
were analyzed and quantiﬁed by two pathologists (n= 3/condition)
Histology % of E2F1-positive cells Intensity of E2F1 labeling
Normal skin Neg. Neg.
Dermic naevus Neg. Neg.
Dermic naevus Neg. Neg.
Primary melanoma (Breslow <1mm) 20% Weak (nucl)
Primary melanoma (Breslow >4mm) 30% Weak (nucl)
Metastatic melanoma #1 40% Moderate to strong (nucl and cyto)
Metastatic melanoma #2 50% Moderate to strong (nucl and cyto)
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E2F1 depletion alone reduced cell viability (Fig. 5b),
combination of BRAF and E2F1 inhibition resulted in
increased cell death in BRAF mutant lines (Fig. 5b). Using
double-labeling Annexin V+DAPI and ﬂow cytometry,
we observed a strong increase in the percentage of
double-positive cells that are characteristic of apoptotic
cell death, when combined treatments were used (Fig. 5c).
To conﬁrm this apoptosis, western blot analysis indicates
that the combination of BRAF inhibitor treatment and
E2F1 depletion drastically decreased the pro-form of the
caspase-3 and Bcl-2 and led to increased PARP cleavage
(Fig. 5d). We next used a series of different BRAF-
resistant melanoma cells15. Intriguingly, the inhibition of
E2F1 induced loss of cell viability of sensitive and BRAF
inhibitor-resistant melanoma cells (Fig. 5e). In order to
determine whether apoptosis could be responsible for the
apparent cell death, western blot analysis indicated that
E2F1 depletion decreases pro-form of the caspase-3 and
Bcl-2, and an increase in PARP cleavage, p53 and p27 (Fig.
5f). To conﬁrm this apoptosis, we quantiﬁed Annexin V
+DAPI co-stained cells by ﬂow cytometry and have
shown that inhibition of E2F1 led to an increase in
Annexin V+DAPI labeling in double-labeled cells that
were resistant to PLX4032 (Fig. 5g). In parallel, we
observed that E2F1 inhibition is also able to induce DNA
damage in A375-resistant melanoma cells as indicated by
increased expression of γH2AX (Fig. 5f). We next carried
out experiments to evaluate the effects of E2F1 blocking
in combination with BRAF inhibitor, PLX4032, in BRAF
inhibitor-resistant melanoma cells. As presented in Supp
Figure 6, we observed that co-inhibition of BRAF by
PLX4032 and E2F1 by siRNA did not increase apoptosis
(PARP cleavage and Annexin V-positive cells) or DNA
damage (γH2AX) in comparison to E2F1 inhibition alone.
These results indicate that BRAF inhibitors do not
increase the death induced by inhibition of E2F1.
Discussion
Metastatic melanoma is notoriously refractory to con-
ventional cancer therapies and remains largely resistant to
current targeted therapies. Our study has demonstrated
that inhibition of E2F1 (transcription factor from E2F1
family) is effective in decreasing melanoma cell viability in
both sensitive and resistant metastatic melanoma cells.
E2F1 is the most studied member of the family and
presents several yet opposing roles in the control of cell
growth and apoptosis, depending on the cell type or tissue
contexts. E2F gene ampliﬁcation has been described in
various cancer cell lines and tumor types11. Further,
higher levels of E2F1 are frequently associated with high-
grade tumors and poor patient survival prognosis13,16.
Our results are in agreement with those in the literature
showing higher expression of E2F1 in metastatic mela-
noma and bring novel data regarding its mechanisms of
effect, and, importantly, give an important insight into its
potential beneﬁcial role in resistive patients.
The role of E2F1 in apoptosis is contradictory. It has
been reported that the ambivalent pro-apoptotic or anti-
apoptotic function of E2F1 depends on the tissue type
and/or cellular contexts. In our system, we conﬁrm that
inhibition of E2F1 using siRNA in melanoma cells leads to
apoptotic cell death. This was demonstrated using mul-
tiple techniques including the number of Annexin V/
DAPI-double-positive cells, PARP cleavage, activation of
caspase-3, and anti-apoptotic protein Bcl-2. We also
demonstrated that E2F1 inhibition in melanoma cells
induces a cellular phenotype displaying several hallmarks
of senescence, such as larger but ﬂatter cells with more
(see ﬁgure on previous page)
Fig. 2 Inhibition of E2F1 by RNAi depletion decreases cell viability in melanoma cells in p53 dependent-manner. a The melanoma cell line
A375 was transfected with control siRNA (siCtl 50 nM) or two different E2F1 siRNA (siE2F1 50 nM). At the indicated times, viable cells were counted
using the trypan blue dye exclusion method. The results are expressed as percentages of control. In parallel, a crystal violet stain was used under the
same conditions. b Indicated melanoma cell lines 1205Lu, Mel-501, or human melanoma cells freshly isolated from tumors were transfected with siCtl
(50 nM) or siE2F1 (50 nM). After 4 days, viable cells were counted using the trypan blue dye exclusion method. The results are expressed as
percentage of the control. c A375 cells were transfected with siCtl (50 nM) or siE2F1 (50 nM), and after 24 h, they were transfected with a p53-
responsive promoter reporter (PG13-luc). After 24 h, luciferase activity was measured and normalized to β-galactosidase activities. p53 activator,
actinomycin D (10 µg/ml), was used as a positive control. For a–c, cells were lysed and analyzed by western blotting using the indicated antibodies.
HSP90 was used as a loading control. d 1205Lu melanoma cell line or human melanoma cells freshly isolated from tumors were transfected with siCtl
or siE2F1 for 4 days. E2F1 and p53 levels were determined by western blot analysis. HSP90 was used as a loading control. e Immunoﬂuorescence
pictures of A375 melanoma cells transfected with siCtl or siE2F1. p53 was labeled with speciﬁc antibody (magenta), DNA was visualized with DAPI
(blue), and phalloidin was visualized in red. Hydroxyurea (HU) was used as a positive control. A representative picture is shown. f A375 melanoma
cells and human melanoma cells freshly isolated from tumors were co-transfected with siCtl or siE2F1 and siRNA against p53 (sip53 50 nM). After
4 days, viable cells were counted using the trypan blue dye exclusion method. In parallel, cells were lysed and analyzed by western blot using the
indicated antibodies. HSP90 was used as a loading control. g Mewo and SK-Mel 28 melanoma cells were infected with adenovirus encoding a WT
form of p53 (Adp53) or with a control adenovirus (AdCtl). After 24 h, cells were transfected with siE2F1. After 4 days, viable cells were counted using
the trypan blue dye exclusion method. In parallel, cells were lysed and analyzed by western blotting using the indicated antibodies. HSP90 was used
as a loading control. The results are expressed as percentages of the control and data are means ± SD of three independent experiments performed
in triplicate. *P < 0.05, **P < 0.01, and ***P < 0.001
Rouaud et al. Cell Death and Disease  (2018) 9:527 Page 6 of 12
Ofﬁcial journal of the Cell Death Differentiation Association
granulation and increased senescence-associated-β-gal
(SA-β-Gal) activity. Analyzing the expression of proteins
involved in the control of the cell cycle and senescence
revealed increased p21CIP1 and p27KIP1 when E2F1 activity
is lowered17–20. Our study also highlighted that the crucial
role of p21 and/or p27 is the control of E2F1-dependent
senescence.
The senescence program is often associated with DNA
damage14,21. These observations prompted us to investi-





























































































































































































































Fig. 3 Inhibition of E2F1 induces p53-dependent apoptosis. a A375 melanoma cells were transfected with siCtl (50 nM) or two different siE2F1
(50 nM) for indicated times. At the end of experiment, cells were co-stained with Annexin V and DAPI to detect dead cells by ﬂow cytometry.
Staurosporine was used as a positive control. In parallel, cells were lysed and analyzed by western blotting using with indicated antibodies. HSP90
was used as a loading control. b, c 1205Lu melanoma cell lines or human melanoma cells freshly isolated from tumors were transfected with siCtl or
siE2F1. b After 4 days, cells were co-stained with Annexin V and DAPI to detect dead cells by ﬂow cytometry. c In parallel, cells were lysed and
analyzed by western blotting using indicated antibodies. HSP90 was used as a loading control. d A375 melanoma cells transfected with siCtl or siE2F1
for indicated times. d Caspase-3 activity was determined by ﬂuorometric assay. H2O2 was used as positive control. e A375 melanoma cells were
transfected with siRNA against caspase-3 (siCasp3 50 nM) or p53 (sip53 50 nM) or co-transfected with siCtl or siE2F1 for 4 days. Cells were co-stained
with Annexin V and DAPI to detect dead cells by ﬂow cytometry. In parallel, cells were lysed and analyzed by western blotting using the indicated
antibodies. HSP90 was used as a loading control. For a, d, e, the results are expressed as percentages. Data are means ± SD of three independent
experiments. *P < 0.05, **P < 0.01, and ***P < 0.001
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Fig. 4 (See legend on next page.)
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following E2F1 inhibition. In agreement with our
hypothesis, we have shown that the senescence mediated
by E2F1 inhibition engages a broad DNA damage
response signaling pathway. In addition, we observed that
inhibition of E2F1 in melanoma cells leads to the presence
of 53BP1 foci and increased γH2AX, two mediators
recruited and phosphorylated at DNA-damaged sites. We
also observed the activation of the critical mediator of
cellular responses to DNA damage, CHK2. Noteworthy,
although we cannot rule out the existence of DNA single-
strand breaks, engagement of the γH2AX/53BP1/CHK2
cascade in E2F1-inhibited cells strongly indicates that the
type of DNA damage is mainly double-strand breaks.
Recent data described that reactive oxygen species (ROS)
play a crucial role in maintaining DNA damage, which is
necessary for a stable arrest of the proliferation that is
characteristic of a senescence program22. As shown here,
E2F1 inhibition leads to increased ROS production, which
could be the initiating factor of this program. However,
our data using N-acetyl cysteine to prevent ROS induction
did not inhibit cell viability and induction of senescence
mediated by siE2F1, suggesting that ROS are not involved
in these process (Supp Figure 3J and data not shown).
Interestingly, these senescence program and DNA
damage response are also independent of apoptosis
mechanism.
One protein that can mediate these different effects is
the tumor suppressor p53. Indeed, p53 functions as a
transcriptional regulator of genes involved in cell cycle
arrest, autophagy, senescence, and apoptosis pathways.
First, we demonstrated that the inhibition of E2F1
increases p53 expression and activity. Second, melanoma
cells harboring a mutated TP53 gene exhibited no mod-
iﬁcation of melanoma viability after E2F1 inhibition.
Identical results were obtained when we invalidated
endogenous p53 in melanoma cells. This effect is not
associated with apoptosis, DNA damage, or senescence
induction. Interestingly, rescuing the expression of TP53
in p53-knockdown cells restores E2F1 inhibition effects,
further indicating the key function of p53 in mediating the
effects of E2F1 inhibition in our cellular models. In
addition, our studies suggest that E2F1 functions
upstream of p53 in the crosstalk between these two
transcription factors in the context of apoptosis and
senescence.
In parallel, we have evaluated the anti-melanoma
activity of the E2F inhibitor HLM006474 in intact mela-
noma cells and in a mouse model of melanoma xenograft.
As previously described, HLM006474 is not speciﬁc for
E2F1 as it can also inhibit E2F49. In melanoma cells,
HLM006474 induces similar effect as observed with spe-
ciﬁc E2F1 siRNA. As blocking E2F4 also inhibited mela-
noma cell viability, it is not excluded that the effects of
HLM006474 could also be mediated by E2F4 inhibition.
Further studies will be necessary to determine the
respective contribution of E2F1 and E2F4 in the effects of
HLM006474 in melanoma cells.
Importantly, we found that short-term administration
of HLM006474 dramatically reduces the development of
melanoma tumors in mice. In addition, HLM006474
induces no apparent toxicity, as the body weight and
overall appearance of mice given an HLM006474 regimen
were not different from controls. To determine whether
the molecular events observed in melanoma cells were
also found in xenograft mice, we performed western blot
analysis which indicated p53 activation induced by
HLM006474, induction of apoptosis, and DNA damage in
tumors of treated mice. In mice, we saw no effect on
normal cells (melanocytes/keratinocytes) demonstrating
speciﬁcity of E2F inhibitor in melanoma cells.
The development of resistance to BRAF inhibitors is a
major obstacle in targeted therapy for melanoma. Our
data clearly indicate that E2F1 inhibition potentiates the
anti-proliferative and pro-apoptotic effects of BRAF
inhibitors, PLX4032 and dabrafenib, in melanoma cell
lines sensitive to BRAF inhibitor. The restoration of p53
(see ﬁgure on previous page)
Fig. 4 Inhibition of E2F1 induces senescence with activation of DNA damage in a p53-dependent and p27-dependent manner. a A375
melanoma cells were co-transfected with siCasp3 and siCtl or siE2F1. After 4 days, viable cells were counted using the trypan blue dye exclusion
method. The results are expressed as the percentage of control. In parallel, cells were lysed and analyzed by western blotting using with indicated
antibodies. HSP90 was used as a loading control. b A375 melanoma cells were transfected with siCtl or two different siE2F1 for indicated times. Cells
were then analyzed by ﬂow cytometry for the relative size and cell granularity. Hydroxyurea (HU) was used as positive control. c Indicated melanoma
cell lines or human melanoma cells freshly isolated from tumors were transfected with siCtl or siE2F1. After 4 days, cells were stained for SA-β-Gal
activity. A representative picture is shown. d Immunoﬂuorescence pictures of A375 melanoma cells transfected with siCtl or siE2F1 for 4 days. 53BP1
was labeled with speciﬁc antibody (green), DNA was visualized with DAPI (blue), and phalloidin was visualized with red. Hydroxyurea (HU) was used
as a positive control. A representative picture is shown. e A375 melanoma cells were transfected with siCtl or two different siE2F1 for indicated times.
Cell lysates were analyzed by western blotting using the indicated antibody. Actin was used as a loading control. One representative experiment of
three is shown. f–h A375 melanoma cells were co-transfected with sip53 or siCasp3 or sip27 and siCtl or siE2F1. f Cells were analyzed by ﬂow
cytometry for the relative size and cell granularity. The results are expressed as percentage of control. g Cells were stained for SA-β-Gal activity. A
representative picture is shown. h Cells were lysed and analyzed by western blotting using the indicated antibodies. HSP60 was used as a loading
control. For a, b, f, the results are expressed as percentages of the control. Data are means ± SD of three independent experiments. *P < 0.05, **P <
0.01, and ***P < 0.001
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Fig. 5 E2F1 inhibition sensitizes melanoma cells to targeted therapies and induces the death of BRAF inhibitor-resistant melanoma cells. a
A375 melanoma cells were treated with DMSO or PLX4032 (5 μM) or dabrafenib (300 nM) for 2 days. Cells were lysed and analyzed by western
blotting using the indicated antibodies. b–d A375 melanoma cells were transfected with siCtl or siE2F1, and 36 h later, cells were treated with BRAF
inhibitors, PLX4032 (1, 2.5, or 5 µM) or dabrafenib (50, 150, or 300 nM) for 48 h. b Viable cells were counted using the trypan blue dye exclusion
method. The results are expressed as the percentage of control. c Cells were co-stained with Annexin V and DAPI to detect dead cells by ﬂow
cytometry. d In parallel, cells were lysed and analyzed by western blotting using the indicated antibodies. HSP90 was used as a loading control. e–g.
A375 melanoma cells sensitive (S) or resistant (R) to PLX4032 or WM9 sensitive (S) or resistant (R) to PLX4032 were transfected with siCtl or siE2F1 for
3 days or treated with PLX4032 for 48 h. e Viable cells were counted using the trypan blue dye exclusion method. The results are expressed as the
percentage of control. f In parallel, cells were lysed and analyzed by western blotting using the indicated antibodies. HSP90 or Erk2 was used as a
loading control. g A375 cells S and R were co-stained with Annexin V and DAPI to detect dead cells by ﬂow cytometry. For b, c, f, g, data are means ±
SD of three independent experiments. *P < 0.05 and **P < 0.01
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activity in melanoma p53-deﬁcient cells is effective in
increasing the sensitivity of melanoma cells to the BRAF-
MAPK inhibitor pathway23,24. Given that the effects of
E2F1 inhibition on cell viability are p53 dependent, we
postulate that these effects on BRAF inhibitor sensitivity
are mediated through p53 activation. This hypothesis is
currently tested in our laboratory. Furthermore, our data
also indicate that BRAF inhibitors reduce E2F1 expression
and this is likely to be due to G1/S arrest observed in
response to these compounds. We next performed
experiments in BRAF inhibitor-resistant melanoma cells.
There have been multiple mechanisms previously pro-
posed25. We failed to detect classical secondary mutations
in NRAS, KRAS, or MEK, or elevated levels of BRAF or
alternatively splice isoforms15. E2F1 inhibition decreased
the viability of melanoma cells with acquired resistance to
BRAF inhibitor through the induction of apoptosis and
DNA damage. We were not able to determine if the loss
of E2F1 led to senescence process in the resistant cells due
to the large cell death observed. Further, our experiments
indicate that BRAF inhibitors do not increase the death
induced by inhibition of E2F1 in melanoma cells resistant
to BRAF inhibitors.
Taken together, E2F1 loss enhances sensitivity of mel-
anoma cells to targeted therapies and induces the death of
BRAF inhibitor-resistant melanoma cells. Collectively,
these data suggest that E2F1 is a critical mediator of
melanoma drug sensitivity and may serve as an important
target for novel therapeutic strategies. Further, this study
provides compelling data to support future evaluation of
HLM006474 in clinical trials and strengthen the hypoth-
esis that E2F inhibitors could be useful as a new ther-
apeutic approach for melanoma treatment.
Materials and methods
Reagents and antibodies
Trypan blue, Dulbecco's modiﬁed Eagle's medium,
RPMI, trypsin, and siRNA were purchased from Life
Technologies. Annexin V and DAPI were purchased from
Roche Applied Science. Dabrafenib and PLX4032 were
purchased from Euromedex. Antibodies against HSP90,
E2F1, E2F4, Rb, and phospho-Rb were from Santa Cruz
Biotechnology (TEBU, Le Perray en Yvelines, France).
Antibodies against PARP, pro-caspase-3, p38, phospho-
p38, MDM2, Chk2, p-Chk2, p21, and p27 were from BD
Bioscience (Pont de Claix, France) and anti-H2AX was
from Merck Millipore (Fontenay-sous-Bois, France).
The E2F1 siRNA number 1 corresponds to a Smart pool
(Dharmacon ref: L-003259-00-0005) and the siRNA
number 2 was purchassed to Ambion (Ref: 4390824).
Cell cultures
Melanocytes and ﬁbroblasts were prepared as descri-
bed26. Different melanoma cell lines were purchased from
American Tissue Culture Collection. Resistant melanoma
cell lines A375 and WM9 were a gift from Pr. Marchetti
and as described15 (see Supplemental Materials and
methods). Fresh sterile tissues were obtained as surgical
waste from patients diagnosed for metastatic melanoma at
the Nice CHU hospital and treated as reported27.
siRNA transfection
Transfection of duplex siRNAs was as described28.
Trypan blue exclusion assay
Trypan blue staining was conducted as described29.
Luciferase assay
Luciferase assays were conducted as described29.
Western blot assay
Western blot analyses were performed as described30.
Immunoﬂuorescence
Immunoﬂuorescence staining was performed as
described31.
SA-β-Gal assay
SA-beta-Gal Kit (Cell Signaling Technology) was used
to histochemically detect β-galactosidase activity.
Flow cytometry analysis
Cells were stained with DAPI and Annexin V or Cell
ROX Deep Red and analyzed using ﬂuorescence-activated
cell sorter (MACSQuant Analyzer) and MACSQuantify
software as described32.
In vivo murine cancer model
Animal experiments were carried out in accordance
with French law and were approved by a local institutional
ethical committee CIEPAL. A375 cells were sub-
cutaneously inoculated in the left dorsal side of 6-week-
old female athymic nude nu/nu mice (Harlan, Gannat,
France). The tumor size was assessed using calipers, and
the volume was calculated according to the formula:
tumor volume (mm3)= tumor width × length2 × 0.5. At
the end of the experiment, mice were killed, tumors were
excised, and then analyzed.
Statistical analysis
Unless stated otherwise, experiments shown were
representative of at least three independent experiments.
All data were presented as means ± standard deviation.
Statistical analysis was performed using the Student's t
test: *P < 0.05 vs. control, **P < 0.01 vs. control, and *** P
< 0.001 vs. control deemed statistically signiﬁcant. For
microarray analysis, Mann–Whitney test was
performed.
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